Monocentric, prospective observational study to assess bowel inflammation in children with chronic inflammatory bowel disease (IBD) using multispectral optoacoustic tomography (MSOT).
Inflammatory bowel diseases (IBD) play a major role in child and adolescent medicine. 25 % of patients with IBD are younger than 18 years of age at diagnosis and 25 % of those are even younger than 10 years of age at disease onset. The incidence of IBD in children and adolescents is 5-11/100 000 in Germany. IBD comprises mainly two entities, namely Crohn's disease (CD) and ulcerative colitis (UC). Patients with CD develop chronic and intermittent transmural inflammation of the gastrointestinal tract, which manifests with symptoms like diarrhea, hematochezia, abdominal pain, fatigue and malnutrition. This often results in weight loss and an increased risk of numerous complications such as the development of fistulas, perforations and intestinal strictures. In addition, growth disturbances and delayed onset of puberty are more frequent. Overall, the course of the disease can only be compared between children and adults to a very limited extent, as the disease often progresses more rapidly and severely in children. Accordingly, the procedure and recommendations for children with CD differ from those of adults. In addition to clinical scores, laboratory chemical parameters (blood count, CrP, calprotectin) and imaging diagnostics (endoscopy, ultrasound, MRT) are available to assess disease activity. However, the latter are only of limited use for routine monitoring due to their invasiveness, the need for sedation and the use of contrast agents. Multispectral Optoacoustic Tomograph (MSOT) on the other hand allows, comparable to sonography, a non-invasive, quantitative imaging of the composition of target tissues in children without sedation. Previous studies have shown that the quantitative determination of hemoglobin provides information on blood flow and inflammatory activity in the bowel of adult patients with Crohn's disease. In this pilot study, the intestinal wall of children will be characterized by MSOT to differentiate between CD, UC, and unclassified inflammatory bowel disease (U-IBD) and to quantify changes and correlate them with routine parameters. This could lead to a new possibility of non-invasive evaluation of disease forms and activity comparable to previous findings in adult patients with CD.
Study Type
OBSERVATIONAL
Enrollment
23
Non-invasive transcutaneous MSOT imaging of the bowel wall (terminal ileum, ascending caecum/colon, transverse colon, descending colon, and sigmoid colon).
University Hospital Erlangen
Erlangen, Bavaria, Germany
Quantitative amount of oxygenated/deoxygenated hemoglobin in a.u.
Oxygenated/deoxygenated hemoglobin signals in the intestinal/bowel wall of children with different entities of IBD (CD vs. UC vs. U-IBD) derived by MSOT in arbitrary units (a.u.)
Time frame: Single time point (1 day)
Quantitative amount of fibrosis/collagen signal in a.u.
fibrosis/collagen signals in the intestinal wall of children with different entities of IBD (CD vs. UC vs. U-IBD) derived by MSOT in arbitrary units (a.u.)
Time frame: Single time point (1 day)
Quantitative amount of single wavelength signal in a.u.
single wavelength signals in the intestinal wall of children with different entities of IBD (CD vs. UC vs. U-IBD) derived by MSOT in arbitrary units (a.u.)
Time frame: Single time point (1 day)
Optoacoustic spectrum in a.u.
Optoacoustic spectrum in the intestinal wall of children with different entities of IBD (CD vs. UC vs. U-IBD) derived by MSOT in arbitrary units (a.u.)
Time frame: Single time point (1 day)
Endoscopic extent of inflammation
Assessment of inflammation in endoscopies within different entities of IBD (CD vs. UC vs. U-IBD)
Time frame: Single time point (1 day), +/- 7 days from MSOT Imaging
Histological extent of inflammation and fibrosis
Assessment of inflammation and fibrosis in histological samples from biopsies within different entities of IBD (CD vs. UC vs. U-IBD)
Time frame: Single time point (1 day), +/- 7 days from MSOT Imaging
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Clinical evaluation
Assessement of clinical disease status by PCDAI or PUCAI according to the CED within different entities of IBD (CD vs. UC vs. U-IBD)
Time frame: Single time point (1 day)
Ultrasound
Assessment of disease status by ultrasound within different entities of IBD (CD vs. UC vs. U-IBD)
Time frame: Single time point (1 day), +/- 1 day from MSOT Imaging
Laboratory parameters (blood - c-reaktive protein (CrP))
Assessment of disease status by laboratory parameters (CrP) within different entities of IBD (CD vs. UC vs. U-IBD)
Time frame: Single time point (1 day), +/- 7 day from MSOT Imaging
Laboratory parameters (stool - Calprotectin)
Assessment of disease status by laboratory parameters (Calprotectin) within different entities of IBD (CD vs. UC vs. U-IBD)
Time frame: Single time point (1 day), +/- 14 day from MSOT Imaging
MRI
Assessment of disease status by MRI (if applicable) within different entities of IBD (CD vs. UC vs. U-IBD)
Time frame: Single time point (1 day), +/- 14 day from MSOT Imaging